Experimental trio therapy takes on recurrent glioblastoma

NCT ID NCT04225039

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tests whether combining two immunotherapy drugs (INCAGN1876 and INCMGA00012) with targeted radiation can help people with recurrent glioblastoma, an aggressive brain cancer. The 39 participants receive the drugs before and after surgery to remove the tumor, plus radiation over three days. The goal is to see if the treatment shrinks tumors and improves survival, while monitoring side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
INCAGN1876 (immune-stimulating antibody), INCMGA00012 (PD-1 inhibitor), and stereotactic radiosurgery (focused radiation)
What this could lead to
If successful, this combination could offer a new treatment option for recurrent glioblastoma, potentially slowing tumor growth and extending survival.
What could go wrong
This is a small, early-phase trial (39 participants) with no control group, so results may not be definitive. The treatment involves strong immune drugs and radiation, which can cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE ASTROCYTIC GLIOMA, IDH-WILDTYPE, WITH MOLECULAR FEATURES OF GLIOBLASTOMA, WHO GRADE IV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.